Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2017 07:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments

RA’ANANA, Israel and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
November 09, 2017 08:30 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Present at the Jefferies 2017 London Healthcare Conference

RA’ANANA, Israel and NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
November 08, 2017 08:30 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Host Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017

RA’ANANA, Israel and NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
November 06, 2017 08:30 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder

RA’ANANA, Israel and NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
November 02, 2017 08:30 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors

RA’ANANA, Israel and NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
October 26, 2017 08:30 ET | Source: UroGen Pharma Ltd.

UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs

RA’ANANA, Israel, and NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
September 06, 2017 08:30 ET | Source: UroGen Pharma

UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development

RA'ANANA, Israel, and NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in...
September 05, 2017 08:30 ET | Source: UroGen Pharma

UroGen Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

RA'ANANA, Israel, and NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in...
August 29, 2017 08:30 ET | Source: UroGen Pharma

UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC)

RA’ANANA, Israel and NEW YORK, Aug. 29, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
August 14, 2017 16:05 ET | Source: UroGen Pharma

UroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments

Completed Initial Public Offering Raising $66.9 Million in Gross Proceeds Continuing Enrollment of Patients in the Phase 3 OLYMPUS Clinical Trial of MitoGel™ for the Treatment of Low-Grade Upper...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right